TL;DR
This systematic review consolidates evidence on amnion's use as a scaffold for cartilage regeneration, finding it consistently promotes better outcomes in preclinical models and shows promise in early clinical trials. While amnion is a promising biomaterial, further standardization and rigorous clinical trials are needed to fully realize its therapeutic potential.
What Problem Does This Paper Address?
Cartilage, crucial for joint function, has poor self-healing capabilities, often leading to osteoarthritis. Current treatments have limitations, driving the need for advanced tissue engineering solutions. Amnion (amniotic membrane) has emerged as a promising biomaterial for cartilage regeneration due to its availability, low immunogenicity, and supportive microenvironment. However, a comprehensive overview of its efficacy across various preclinical and clinical studies was lacking, hindering its translation into widespread clinical application. This review addresses this gap by systematically evaluating the existing evidence on amnion's effectiveness as a scaffold for cartilage repair.
Methods
This study is a systematic review, adhering to PRISMA guidelines. Researchers searched three major databases (PubMed, Web of Science, Scopus) for relevant articles published between January 2000 and December 2025. They used keywords like "cartilage damage," "cartilage injuries," "amnion," and "amniotic membrane." Inclusion criteria focused on preclinical (in vitro, ex vivo, in vivo) and clinical studies using amnion as a scaffold for cartilage defect repair. Studies using only amnion-derived cells or only the chorion layer were excluded. The quality of evidence was assessed using the OHAT risk of bias tool for preclinical studies and the MINORS tool for clinical studies.
Datasets
Not applicable. This paper is a systematic review of existing literature and does not involve the creation or use of new datasets for training or evaluation.
Key Insights and Ideas
- Amnion's Versatility: Amnion proves effective across various processing methods (fresh, air-dried, cryopreserved) and forms (intact, de-epithelialized, decellularized), suggesting robustness in its regenerative properties.
- Cellular Synergy: While amnion alone shows benefits, seeding it with cells like chondrocytes or mesenchymal stem cells (MSCs) consistently enhances chondrogenic differentiation and tissue integration.
- Preclinical Promise: The overwhelming majority of studies are preclinical, consistently demonstrating amnion's ability to support cell attachment, proliferation, and the expression of cartilage-specific markers (like Type II collagen).
- Clinical Gaps: The clinical evidence base is extremely limited, with only one study providing preliminary but positive results, highlighting a significant translational hurdle.
- Standardization is Key: The wide variation in amnion procurement, processing, and experimental design across studies makes direct comparisons challenging and underscores the need for standardization.
Key Results
The review identified 19 relevant studies.
- In Vitro: Amnion scaffolds consistently supported better cell attachment, viability, and proliferation compared to controls. They also promoted higher expression of cartilage-related markers.
- Ex Vivo & In Vivo: Amnion-treated groups showed improved cartilage quality, better integration, higher histological scores, and increased Type II collagen presence. Studies in rabbit and sheep models demonstrated positive outcomes, with some reporting hyaline cartilage-like tissue formation.
- Clinical: The single clinical study reported significant improvements in patient-reported outcomes (KOOS scores for sports/recreation and quality of life) and reduced pain (VAS scores). MOCART scoring indicated complete defect repair in most subjects.
Limitations and Future Work
Limitations: * Limited Clinical Data: The most significant limitation is the scarcity of clinical evidence, with only one study available for review. This prevents robust conclusions about amnion's efficacy and safety in human patients. * Heterogeneity in Studies: Variations in amnion processing, cell types used, defect models, and outcome measures across preclinical studies make direct comparisons and meta-analyses difficult. * Reporting Inconsistencies: There was inconsistency in reporting defect dimensions in in vivo studies. * Exclusion of OA Models: While excluding osteoarthritis (OA) models was justified to focus on focal defects, it means the review doesn't directly address amnion's role in managing this systemic disease.
Future Work: * Prioritize Clinical Trials: Future research should focus on Phase I and Phase II clinical trials, ideally randomized controlled trials (RCTs), comparing amnion scaffolds to existing treatments. * Standardize Protocols: Developing standardized protocols for amnion procurement, processing, and manufacturing is crucial for ensuring product consistency and enabling clinical translation. * Harmonize Outcome Measures: Clearly defined clinical indications and harmonized outcome measures (including imaging techniques) are needed for cross-study comparisons. * Larger Sample Sizes & Longer Follow-up: Clinical studies should employ larger sample sizes and longer follow-up periods to enhance statistical power and assess long-term efficacy and safety. * Investigate Composites: Further research into composite scaffolds combining amnion with other biomaterials could enhance mechanical strength and biological properties.
Summary updated